Castle Biosciences (CSTL) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Revenue: $83 million for Q3 2025, a significant increase from $80.7 million in Q3 2024.

Test Report Volume: 26,841 reports, a 36% increase year-over-year.

DecisionDx-Melanoma Reports: 10,459, marking a 12% year-over-year increase and surpassing 10,000 reports in a single quarter for the first time.

DecisionDx-SCC Reports: 4,186 reports, maintaining high volume without proactive marketing.

Gross Margin: 74.7%, down from 79.2% in Q3 2024; adjusted gross margin was 76.8%, down from 81.9%.

Net Loss: $0.5 million, compared to a net income of $2.3 million in Q3 2024; diluted loss per share was $0.02.

Adjusted EBITDA: $9.2 million, down from $21.6 million in the same quarter last year.

Cash Position: $287.5 million in cash, cash equivalents, and marketable securities.

2Strategic Updates and Business Highlights

Launch of AdvanceAD-Tx: A new test for guiding systemic treatment selection for moderate to severe atopic dermatitis, targeting a $33 billion market.

Clinical Validation: AdvanceAD-Tx demonstrated the ability to identify patients likely to respond to JAK inhibitors versus Th2-targeted therapies.

DecisionDx-SCC Updates: New peer-reviewed evidence supports its clinical utility, enhancing its role in managing high-risk squamous cell carcinoma.

TissueCypher Growth: Achieved 10,609 test reports, a 75% year-over-year increase, indicating rising recognition among clinicians.

Reimbursement Efforts: Ongoing efforts to secure reimbursement for AdvanceAD-Tx, with expectations of immaterial revenue contribution in 2026.

3Forward Guidance and Outlook

Revenue Guidance: Increased for 2025 to a range of $327 million to $335 million, up from $310 million to $320 million.

DecisionDx-Melanoma Volume Growth: Expected to maintain high single-digit growth for the full year 2025.

SCC Test Revenue: Anticipated to be modest, with a conservative outlook on future contributions.

4Bad News, Challenges, or Points of Concern

Declining Gross Margin: Notable decrease in gross margin metrics, raising concerns about cost management amidst rising expenses.

Net Loss: Transition from profitability to a net loss compared to the previous year, indicating potential operational challenges.

SCC Test Reimbursement Uncertainty: Ongoing uncertainty regarding Medicare coverage decisions and the impact on SCC test utilization.

Market Penetration Risks: While there is significant potential for growth, the company faces challenges in expanding physician adoption and navigating reimbursement landscapes.

5Notable Q&A Insights

Market Addressability for AdvanceAD-Tx: Approximately 13.2 million patients with moderate to severe atopic dermatitis, with an estimated 10-20% being Medicare age.

Reimbursement Pathways: Discussions around multiple reimbursement avenues, including commercial payers and Medicare contractors like Novitas and MolDx.

SCC Volume Stability: Despite flat quarter-over-quarter volumes, management expressed confidence in the clinical value of the SCC test.

Sales Force Impact: Refocusing the dermatology sales team has contributed to growth in DecisionDx-Melanoma, with both new and existing clinicians driving volume increases.

FDA Approval Discussion: Pursuing FDA approval for DecisionDx-Melanoma, though management does not expect immediate changes to Medicare rates as a result. This summary encapsulates the key points from Castle Biosciences' Q3 2025 earnings call, highlighting both achievements and challenges as the company navigates its growth trajectory in the dermatology testing market.